Table 5.

Summary or studies on the use of salvage stereotactic radiosurgery for recurrent glioblastoma

Institution (year)	#rGB/# total	Median dose [range] (Gy)	Prescription	MS (M)	Late toxicity
Brigham & Women's Hosp. (1995) [22]	86/86	13 [6-20]	50–90% IDL Median 80%	10	19 pathologic necrosis 1 CN palsy
U. Pittsburgh (1997) [23]	19/107	NR	NR	30	1 symptomatic necrosis 12 pathologic necrosis (of 60 GB patients)
U. Minnesota (1999) [24]	27/46	17 [9-40]	30–90% IDL Median 50%	7	8 pathologic necrosis 6 clinical necrosis
U. Wisconsin (1999) [25]	NR/30	NR	50–80% IDL	7	NR
Cleveland Clinic (2000) [26]	23/23	15 [12-20]	50–80% IDL	10	1 pathologic necrosis 2 increased seizures
UCSF (2002) [27]	14/26	[~10–22]	50% IDL	10	Not assessable
UCSF (2002) [27]	39/54	[~12–18] + marimastat	25–30% IDL	9	Not assessable
U. Heidelberg (2005) [28]	32/32	15 [10-20]	80% IDL covers tumor	10	None
MDACC (2005) [29]	40/40	NR	NR	11	8 pathologic necrosis
Henry Ford (2007) [30]	26/26	NR	18 Gy at margin	9	NR
Current series	18/33	15 [9-20]	80% IDL covers tumor	7	See text

Abbreviations: rGB = recurrent glioblastoma, GB = glioblastoma, SRS = stereotactic radiosurgery; IDL = isodose line. NR = not reported.